

kneu
HEALTH


Closing the Gap in Neurology

Starting with Parkinson's and Dementia

A spin-out from



UNIVERSITY OF
OXFORD





Neurology care today

\$400B per year

Spent on chronic
neurology conditions

25% acute beds

Occupied by patients
with dementia



Complex Conditions

	40+	Symptoms
X	3-10	Medications per day
X	6	Monthly visits
X	ATT	And other therapies

=

Large combination of fluctuating symptoms, medications and therapies

k

Underdiagnosed Undertreated, No follow up



90% of people with dementia found hospital admission **frightening and confusing**

43% of people with dementia in hospital were due to **urinary tract and chest infections (treatable in the community)**

25% of acute hospital beds occupied by patients with dementia

On average people with dementia stay in hospital **more than twice as long** as other patients aged +65

Dementia (incl. Alzheimer's) has been the **leading cause of death** in UK & USA

01 **Poor screening** | Inadequate early recognition of cognitive changes


02 **Long waiting times** | Lack of timely diagnosis

03 **Workforce constraints** | Lack of post-diagnosis care coordination

= Avoidable hospital admissions

k Our Smartphone-based Solution


Leveraging over 10 years of research & data science



Smart phone based patient platforms
PATENT PENDING




Fully remote active and passive data collection



AI driven insights




Kneu's Digital Cognitive Assessments



Digital Symbol Substitution

Processing Speed

Match as many symbols with their digit



Trail Making

Executive Function

Connect the dots in the correct sequence




Object in Scene

Immediate & delayed recall memory


- Identification performance
- Localization performance

A




All strongly distinguish between Alzheimer's Disease (AD) & elderly health controls (EHC) across multiple cognitive domains

B




Correlates with ACE-III in EHC, AD and MCI – sensitive to differing degrees of impairment

C



Significant correlations with multiple plasma biomarkers

D




Combination of plasma biomarker + DCA have highest AUC on group classification of AD vs EHC

Our DCA can also predict AD independently of biomarkers ($p < 0.001$) and predict p-tau181 levels ($p < 0.001$) useful for screening

n=46 AD
n=53 EHC

k Kneu's Future End-to-End Digital Neurology Pathway







1st FDA cleared
smartphone medical
device for Parkinson's &
registered for Dementia



Our Product





Evidenced-based, Clinically validated



90%
of clinicians report
better patient care

30%
Increase in patient
knowledge

30%
increase in clinic
efficiency

Reduced hospital admissions
1,000
bed days saved
annually per hospital



Transforms Clinical Practice...



Michele Tagliati • 1st
Professor and Vice Chair of Neurology, Director of Movement Disorders Division...
3h • Edited

Thrilled to share that we've completed our first Remote Therapeutic Monitoring (RTM) visit at Cedars-Sinai for a patient with #Parkinson's disease, using the Neu Health platform — marking a major step forward in bringing precision care to patients beyond the clinic.

Through NeuHealth's #innovative #technology, we are now able to monitor #motor symptoms, #cognitive and #sleep activity, and #medication response in real time, allowing for more personalized and timely interventions. This first RTM visit is not only a clinical achievement, but a glimpse into the #future of Parkinson's care — continuous, connected, and patient-centered.

Grateful to our clinical team, patients, and partners at NeuHealth who are helping us redefine the standard of care.

Caroline Cake Bridget Frommel Nirdesh K Gupta, PhD Cheri Phillips Krystal Hattar

#ParkinsonsDisease #DigitalHealth #RemoteMonitoring #precisioncare
#NeurologyInnovation #RTM #PatientCare #MovementDisorders
#FutureOfMedicine



Dr Michele Tagliati
Director of Movement Disorders Division,
Cedars-Sinai Medical Center.



Healthcare Provider Contracts

+\$11.2M

Raised across seed and pre-seed financing rounds

Dec 2023

Ipswich Hospital



East Suffolk and North Essex
NHS Foundation Trust

Spring 2024

Leeds Hospitals
Ipswich (expansion) +
Colchester Hospitals



The Leeds
Teaching Hospitals
NHS Trust

Fall 2024

Multiple NHS
contracts

Cedars-Sinai
Investment



The Walton Centre
NHS Foundation Trust



Oxford Health
NHS Foundation Trust



Oxford University Hospitals
NHS Foundation Trust



West Suffolk
NHS Foundation Trust



2025

US Pilots with Cedars-Sinai + MGB

1st UK Dementia Pilot



FDA
Clearance

Medicare
Reimbursement



WHY kneu



First-smartphone based, FDA 510-k cleared medical device for Parkinson's Disease and registered for Dementia



Validated in care settings in the UK with leading global institutions – Oxford University



Combines **motor, cognitive, and behavioural** data into the **most comprehensive** remote **neurology dataset globally**



HIPAA-compliant and **EPIC-integrated** ready to scale in US and UK clinical practice



Designed to fit seamlessly into neurology workflows – **no new hardware, minimal staff training, and reimbursable out of the box**

Thank you

We're building the next era of neurology care, one that's smarter, more human, and ready for the realities of Parkinson's and dementia. Your partnership helps bring this vision to life.

Let's move neurology forward, together.



kneu.com



hello@kneu.com



2025 SXSW Europe Venture Spotlight Winner



2024 Winner for Digitising Patient Care in the NHS